Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
100.00%
Operating Margin
86.61%
Net Margin
108.55%
Efficiency Metrics
Revenue per Expense Ratio
5.12
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
35.14%
Income Tax Rate
0.00%
EPS
0.3100000000
Balance Sheet Analysis
Current Ratio
5.59
Cash Ratio
1.37
Working Capital
$27.17M
Debt to Equity
0.47
Debt to Assets
31.23%
Equity Ratio
67.13%
Cash Flow Analysis
Operating Cash Flow Ratio
186.26%
Free Cash Flow Ratio
186.26%
CapEx to Revenue
0.00%
Dividends Paid
$81.74M
Stock Buybacks
$50.00M
Total Shareholder Returns
$131.74M
Cash Position Change
199.52%
Key Takeaways (2023 FY)
Revenue declined by 2.3375186109161%, indicating potential market challenges
Maintained positive net income growth despite revenue changes
Increased R&D investment by 100.00%
Detailed Growth Metrics
Core Performance
Revenue
-2.34%
Net Income
125.74%
EPS
125.83%
Operating Income
0.59%
Operational Efficiency
R&D Expenses
100.00%
SG&A Expenses
-17.82%
Operating Cash Flow
-34.96%
Free Cash Flow
-34.96%
Balance Sheet Health
Assets
-3.38%
Debt
3.49%
Book Value per Share
-0.72%
Inventory
100.00%
Shareholder Returns
Dividends per Share
0.00%
Shares Outstanding
0.00%
Long Term Trends
3Y Revenue/Share
0.01%
5Y Revenue/Share
-19.30%
3Y Dividend/Share
0.00%
5Y Dividend/Share
-22.06%